Consensus or Controversy? — Clinical Investigators Provide Perspectives on the Current and Future Management of Patients with Prostate Cancer
Date and Time: Thursday, February 14; 6:30 PM (dinner buffet to be provided)
Location: San Francisco Marriott Marquis, Yerba Buena Ballroom 9-15 (Lower B2 Level)
CME Provider and Supporter(s): This event is organized and accredited by Research To Practice and is supported by educational grants provided by Astellas Pharma Global Development Inc/Medivation Inc., a Pfizer Company, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC and Sanofi Genzyme.
Event Summary: The Penn State College of Medicine in collaboration with Research To Practice (RTP), will recruit five investigators to serve as the faculty for this CME activity. Prior to the event, the faculty will complete a comprehensive survey designed to document their perspectives on controversial questions and/or challenging management scenarios specific to the treatment of early and advanced prostate cancer. Responses from all 5 investigators will be graphically depicted and integrated into the proceedings. The agenda will be divided into 5 modules, each featuring presentation and discussion of the investigator survey results as well as a faculty member-led didactic review of emerging research findings. Attendees will be invited to use the iPads to answer the same questions posed to the faculty. The results from both cohorts will be juxtaposed throughout the program. Clinicians with iPads will also be able to submit questions or cases to foster additional debate.
Emmanuel S. Antonarakis, MD
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
A. Oliver Sartor, MD
Tulane Medical School
Howard I. Scher, MD
Memorial Sloan Kettering Cancer Center
Matthew R. Smith, MD, PhD
Harvard Medical School
*Additional faculty to be announced
Neil Love, MD- Moderator
Research To Practice
Expert Exchange: Examining the Use of Checkpoint Inhibitors in Bladder Cancer
Date and Time: Thursday, February 14; 6:30 PM
Location: San Francisco Marriott Marquis, Yerba Buena Ballroom, Salon 7 (Lower B2 Level)
CME Provider and Supporter(s): This event organized and accredited by Creative Educational Concepts (CEC Oncology), and is supported by an educational grant provided by AstraZeneca.
Event Summary: The Expert Exchange is an engaging and dynamic format that incorporates elements of a traditional Oxford-style debate to encourage audience involvement and provide flexibility to incorporate breaking data. This interactive event will feature several relevant debates with audience voting on ARS keypads. Debate topics will be cultivated from top issues and will be finalized by expert faculty prior to the activity based on evolving management strategies and recent clinical trial findings. Ongoing hot topics related to ICI treatment include: how to select appropriate treatment for a given patient, how best to sequence ICIs with other therapies, how to incorporate combination immunotherapies, the appropriate duration of checkpoint inhibitor treatment, and how to stop/restart immunotherapy if interrupted by immune-related adverse events.
Andrea B. Apolo, MD
Center for Cancer Research, National Cancer Institute
Arjun V. Balar, MD
Laura and Isaac Perlmutter Cancer Center, NYU Langone Health
Robert Dreicer, MD, MS, MACP, FASCO
University of Virginia Cancer Center, University of Virginia School of Medicine
Ashish M. Kamat, MD, MBBS, FACS
University of Texas MD Anderson Cancer Center
Appropriate Utilization of Checkpoint Inhibitor Therapy: Considerations in Renal Cell Carcinoma and Urothelial Carcinoma of the Bladder
Date and Time: Friday, February 15; 6:45 PM (Dinner and Registration at 6:15 PM)
Location: Hotel Nikko San Francisco, Nikko Ballroom I&II
CME Provider and Supporter(s): This event is organized by ASiM CE, LCC, is accredited by Global Education Group, and is supported by an educational grant provided by Bristol-Myers Squibb.
Event Summary: Continuing advances in the use of immune checkpoint inhibitors for treating genitourinary (GU) cancers have garnered much optimism among both healthcare providers and patients. To date, six immune checkpoint inhibitors are approved for various GU cancer indications, making it quite challenging for clinicians to keep pace with appropriate usage, dosing, adverse event management, and more. To address these challenges, our expert faculty will present current data and evidence regarding utilization of immune checkpoint inhibitors for GU cancers. The focus will be on renal cell carcinoma and urothelial carcinoma of the bladder. Case examples and application to clinical practice will be emphasized.
Nizar M. Tannir, MD, FACP
The University of Texas MD Anderson Cancer Center
Arjun V. Balar, MD
NYU Langone Health